| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.6M | — | +1148.3% |
| R&D Expense | $16.7M | — | +140.1% |
| SG&A Expense | $20.3M | — | +870.2% |
| Operating Income | -$17.3M | — | -131.9% |
| Net Income | -$16.6M | — | -123.3% |
| EPS (Basic) | -$0.97 | — | -120.5% |
| EPS (Diluted) | -$0.97 | — | -120.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $267.8M | — | — |
| Current Assets | $285.6M | +9937.4% | — |
| Total Assets | $292.4M | +3400.1% | — |
| Current Liabilities | $21.9M | -47.6% | — |
| Total Liabilities | $58.3M | -18.0% | — |
| Stockholders' Equity | $234.1M | +473.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$31.1M | — | -180.5% |
| Capital Expenditures | $2.1M | — | — |
| Investing Cash Flow | -$2.1M | — | — |
| Financing Cash Flow | $301.5M | — | +2615.5% |
| Free Cash Flow | -$33.2M | — | -199.4% |